Signal from the log
OMass Therapeutics
310 M$ · Series C · United Kingdom · Biotech
OMass Therapeutics, à Oxford, développe des petites molécules par voie orale. Son programme de tête, OMS1620, bloque le récepteur MC2 des surrénales pour traiter l'hyperplasie congénitale des surrénales et le syndrome de Cushing ACTH-dépendant ; un second vise SLC15A4 dans le lupus. La levée est menée à trois par Bain Capital Life Sciences, Forbion et Novo Holdings.
Verified
Announced on , logged by the watch of 15 October 2026.
- Operation
- Funding round
- Announced amount
- 310 M$
- Stage
- Series C
- Country
- United Kingdom
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Bain Capital Life Sciences , Forbion , Novo Holdings , with Janus Henderson Investors , SV Health Investors , Jefferson Life Sciences
Provenance
Source endpoints
Logged on 15 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.